Radiopharm Theranostics Ltd is focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need.
The company's asset portfolio features four platforms that, combined, target three-quarters of the causes of death from cancer, including treatment for cancers of the lung, breast, head and neck, along with solid tumours like brain metastases and gliomas.